

FORM PTO-1390U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE
(REV 5-93)

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

ATTORNEY'S DOCKET NUMBER

5405.214

U S APPLICATION NO (If known, see 37 C.F.R. 1.51)

09/744133

INTERNATIONAL APPLICATION NO.
PCT/US99/16338

INTERNATIONAL FILING DATE
19 July 1999

PRIORITY DATE CLAIMED
21 July 1998

TITLE OF INVENTION

Transgenic Model of Human Oxidative Stress


APPLICANT(S) FOR DO/EO/US
Michael P. VITEK

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. Below concern other document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.
12. ☒ Copy of assignment document recorded in U.S. Prov. App. S/N 60/093,546 is included.
13. ☐ A **FIRST** preliminary amendment.
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information: Complete IPER and International Search Report, Verified Small Entity Statement

U.S. APPLICATION NO. 09/744133		INTERNATIONAL APPLICATION NO. PCT/US99/16338		ATTORNEY'S DOCKET NUMBER 5405.214	
17. <input checked="" type="checkbox"/> The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO \$860.00 International preliminary examination fee paid to USPTO (37 CFR 1.482). \$770.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$710.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO. \$1000.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4). \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT = \$100.00				CALCULATIONS	PTO USE ONLY
Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
Claims	Number Filed	Number Extra	Rate		
Total Claims	10 -20 =	0	X \$18.00	\$	
Independent Claims	1 -3 =	0	X \$78.00	\$	
Multiple dependent claim(s) (if applicable)			+ \$260.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$100.00	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$50.00	
SUBTOTAL =				\$50.00	
Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$50.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	
TOTAL FEES ENCLOSED =				\$50.00	
				Amount to be refunded	\$
				charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$50.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0220.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: <div style="display: flex; justify-content: space-between; margin-top: 10px;"> <div> Kenneth D. Sibley Myers Bigel Sibley & Sajovec P.A. PO Box 37428 Raleigh, NC 27627 </div> <div> "Express Mail" mailing label number EL733093477US Date of Deposit January 19, 2001 </div> </div>					
<div style="display: flex; justify-content: space-between;"> <div> I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to DO/EO/US, Commissioner for Patents, Washington, D.C. 20231. <i>Vickie Diane Prior</i> Vickie Diane Prior Date January 19, 2001 </div> <div style="text-align: center;">  SIGNATURE </div> </div>					
31,665 REGISTRATION NUMBER					

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: **Michael P. Vitek**

Serial No.: **60/093,546**

Filed: **21 July 1998**

For: **TRANSGENIC MODEL OF HUMAN OXIDATIVE STRESS**

VERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS
(37 C.F.R. § 1.9(f) & 1.27(d))--NONPROFIT ORGANIZATION

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF NONPROFIT ORGANIZATION Duke University

ADDRESS OF NONPROFIT ORGANIZATION Erwin Road
Durham, North Carolina 27706

TYPE OF NONPROFIT ORGANIZATION:

- ☒ UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION
☐ TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE
(26 U.S.C. 501(a) and 501(c)(3))
☐ NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF
STATE OF THE UNITED STATES OF AMERICA
(NAME OF STATE _____)
(CITATION OF STATUTE _____)
☐ WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE
SERVICE CODE (26 U.S.C. 501(a) and 501(c)(3)) IF LOCATED IN THE
UNITED STATES OF AMERICA
☐ WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL
UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA
IF LOCATED IN THE UNITED STATES OF AMERICA
(NAME OF STATE _____)
(CITATION OF STATUTE _____)

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 C.F.R. 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office, under Section 41(a) and (b) of Title 35, United States Code, regarding the invention described in:

- ☐ the specification filed herewith with title as listed above.
☒ the provisional application identified above.
☐ the patent identified above.

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization regarding the above-identified invention. If the rights held by the nonprofit organization are not exclusive, each individual, concern, or organization having

rights in the invention must file separate verified statements averring to their status as small entities and that no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 C.F.R. § 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 C.F.R. § 1.9(d) or a nonprofit organization under 37 C.F.R. § 1.9(e).

Each person, concern, or organization having any rights to the invention is listed below:

Name: _____

Address: _____
☐ Individual ☐ Small Business ☐ Nonprofit Organization

Name: _____

Address: _____
☐ Individual ☐ Small Business ☐ Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 C.F.R. § 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: Joyce McWherter

TITLE IN ORGANIZATION OF PERSON SIGNING: Patent Administrator

ADDRESS OF PERSON SIGNING: Duke University
230 North Building, Research Drive
Durham, North Carolina 27708

SIGNATURE: Joyce McWherter DATE: 10/21/98

TRANSGENIC MODEL OF HUMAN OXIDATIVE STRESS

Michael P. Vitek

This invention was made with Government support under grant numbers 1RO1 AG 13839 and 1RO3 AG 15609 from the National Institutes of Health. The Government has certain rights to this invention.

5

Field of the Invention

The present invention concerns transgenic animals, particularly transgenic mice, that are useful as models of human oxidative stress.

Background of the Invention

10

Nitric oxide is a molecule associated with human diseases of the brain and of peripheral tissues. Pathological roles for nitric oxide include cytotoxic and cytostatic effects upon bacterial invaders and toward cancer cells. The physiological roles for nitric oxide (NO) as an intra-cellular and inter-cellular messenger are the focus of intense investigation. Depending upon the situation tested, the co-localization of nitric oxide with diseased and dying cells, particularly in inflammatory conditions, suggest that NO plays an active role in protecting healthy cells from oxidative challenge or alternatively, directly participates in cellular degeneration.

15

Three different Nitric Oxide Synthase enzymes (NOS) convert arginine into citrulline and nitric oxide. The eNOS form associated with endothelial cells (NOS3 gene) and the nNOS form associated with neuronal cells (NOS1 gene), appear to constitutively produce low levels of nitric oxide. In contrast, phagocytic cells like macrophages and microglia contain an immunological form known as iNOS (also known as inducible NOS)(NOS2 gene) which can be induced to release large amounts of nitric oxide. iNOS activity is highly regulated at the level of transcription. To further complicate this picture, iNOS activity is regulated in a species specific manner

20

25

15

Disclosed is a transgenic mouse whose germ cells and somatic cells contain (i) an inactive mouse inducible nitric oxide synthase gene, and (ii) a transgene encoding the human inducible nitric oxide synthase gene, with the transgene including all regulatory elements of the human inducible nitric oxide synthase gene necessary for human patterns of expression of said transgene in said transgenic mouse. The mice of the invention may contain one or two alleles for the human inducible nitric oxide synthase gene (i.e., one or two NOS2 alleles).

SUBSTITUTE SHEET (RULE 26)

The present invention is explained in greater detail in the specification set forth below.

Detailed Description of the Invention

5 The human NOS2 gene is known and can be obtained in accordance with known techniques. *See, e.g.*, Spitsin, S. et al., *Mol. Med.* **2**, 226-235 (1996); Vitek, M. et al., *BBRC* **240**, 391-394 (1997).

 Mice containing an inactive or inactivated mouse inducible nitric oxide synthase gene (e.g., knockout mice) are known and available from commercial
10 sources (e.g., Jackson Labs, Bar Harbor, Maine, USA).

 The production of transgenic mice can be carried out in view of the disclosure provided herein and in light of techniques known to those skilled in the art, such as described in U.S. Patents Nos. 5,767,337 to Roses et al.; 5,569,827 to Kessous-Elbaz et al.; and 5,569,824 to Donehower et al. (the disclosures of which applicants
15 specifically intend to be incorporated by reference herein in their entirety).

 By "human pattern of expression" is meant that the transgene is expressed in mouse phagocytic cells, particularly activated macrophages and/or activated microglia, and more particularly is meant that lipopolysaccharide (LPS) inducers induce essentially no increase in iNOS activity in phagocytic cells of a mouse of the
20 invention as measured by nitric oxide release as compared to the corresponding wild-type mouse, and the phagocytic cells display low-output nitric oxide release in a mouse of the invention as compared to the corresponding wild-type mouse even when maximally stimulated. In one specific example, a mouse pattern of expression in elicited peritoneal macrophages from the mouse would include stimulation of nitric
25 oxide production by LPS or IFN-gamma, and a human pattern of expression would be a lack of nitric oxide production following stimulation with these agents.

 By "corresponding wild-type mouse" is meant a mouse that does not contain the said transgene, and does contain at least one active mouse inducible nitric oxide synthase gene (e.g., one or two mouse NOS2 alleles).

30 To demonstrate how human iNOS contributes to human inflammatory diseases, described herein are transgenic mice lacking the mouse NOS2 gene (muNOS2 -/-) and containing at least one copy of the human NOS2 gene (huNOS +/-) which are called "Humanized-NOS2" transgenic mice. Specifically disclosed are

how to clone and characterize a PAC clone of human genomic DNA containing the entire 40 kbp of the human NOS2 gene and at least 15 kbp of its promoter-regulatory sequences, and the use of this PAC clone to create and characterize transgenic mice containing the human NOS2 gene. Transgenic mice containing the human NOS2 gene are mated to mice lacking the mouse NOS2 gene (available from Jackson Labs) to generate a hybrid transgenic mouse expressing only human iNOS (NOS2) enzyme, i.e. a "Humanized-NOS2" transgenic mouse. These mice are characterized for the expression of human NOS2 gene products.

An object of the invention is to produce a transgenic mouse whose physiological regulation of iNOS activity mimics that of humans. iNOS activity is tested in the mice to confirm it is regulated in a human-specific or in a mouse-specific pattern in these "Humanized-NOS2" transgenic mice. When the human NOS2 promoter/reporter construct is placed into mouse cells, its activity appears to mimic the human specific pattern and not the mouse activity pattern (Mitsuda et al., 1997; Spitsin et al., 1996). As described herein, the "Humanized-NOS2" transgenic mice also display a human-specific pattern of activity. With such mice, the role of iNOS and its nitric oxide products can be better defined in terms of how humans respond to stimuli typically associated with inflammation and neurodegeneration.

To use the mice as models of human disease, mice are stressed by injecting with myelin fractions to generate Experimental Allergic Encephalomyelitis (EAE), which is a model of Multiple Sclerosis (MS) in humans, and compare the severity of disease in wild-type, NOS2-Knockout and "Humanized-NOS2" transgenic mice treated with and without various inhibitors of Nitric Oxide Synthase. Adjuvant Induced Arthritis (AIA), which is a model of rheumatoid arthritis in humans, is also tested in these mice in a similar fashion. As the balance between superoxide and nitric oxide can define pro-oxidant and anti-oxidant conditions, a human specific pattern of nitric oxide production may correctly predict the role of nitric oxide in human pathological conditions. These "humanized-NOS2" transgenic animals are thus useful as a model to test NOS inhibitors and drugs affecting the arginine cycle.

Virtually all successful screening efforts to find drugs that effectively improve human disease conditions require those drugs to be tested in an animal model. A physiologically-relevant model of human nitric oxide production is herein provided. These animals serve as useful models of nitric oxide production as it pertains to the

generation of oxidative stress, which is implicated in the inflammation and destruction of cells in a wide variety of human inflammatory diseases. An important focus for such study is to measure the pro-oxidant and anti-oxidant potentials of nitric oxide in mouse models of inflammatory disease. It is well known that nitric oxide can
5 combine with superoxide to form the strong oxidant, peroxynitrite, which, for example, can attack tyrosines in proteins to form nitrotyrosine residues as can be detected with monoclonal antibodies (Beckman, 1996). Since nitric oxide is also a radical, it can combine with the peroxynitrite radical to generate a non-radical species with the net effect of inhibiting, for example, protein and lipid oxidation. Thus, drugs
10 which modulate nitric oxide production can be tested in the "Humanized-NOS2" animals described herein for their pro-oxidant and/or anti-oxidant potentials, their ability to relieve pain and suffering associated with inflammation and cell destruction in tissues brought about by release of inflammatory modulators.

As an additional utility, the protein products of genes associated with
15 Alzheimer's disease (AD) can stimulate nitric oxide production. Using primed human monocyte derived macrophages as models of microglia, apolipoprotein-E can stimulate nitric oxide production. These same cells fail to produce nitric oxide in response to treatment with Amyloid-beta peptide (Abeta). Since mouse cells do produce nitric oxide in response to Abeta treatment (Meda et al., 1995), mice differ
20 from humans in their response to stimulation of nitric oxide production (see also Walker et al., 1995). Since studies of microglial-mediated production of nitric oxide in human brains are limited by tissue availability, this "Humanized-NOS2" transgenic mouse provides a convenient animal model in which to study nitric oxide production relevant to that found in humans under physiological and pathological conditions.

25 While the present invention has been explained primarily with reference to mice, it will be appreciated that the invention can be implemented with other mammalian species, such as rats, dogs, cats, and monkeys, in accordance with known techniques, or techniques that will be apparent to those skilled in the relevant arts.

The present invention is explained in greater detail in the following non-
30 limiting examples.

EXAMPLE 1***Cloning and Characterizing the Human-NOS2 gene***

Several PAC clones of human genomic DNA are obtained that are positive for the Promoter/Exon-1 region and for the Exon-27 region of the human NOS2 gene.

- 5 Each clone that contained both the 5' and 3' ends of the human NOS2 gene, is subjected to additional PCR reactions with primer pairs to each of the 27 Exons. Each of these Exon-specific PCR products is sequenced and compared to the reported sequences. A restriction map of each of these clones is made and compared to the reported restriction enzyme map to also ensure that the PAC clone is correct.
- 10 Additional mapping employs Southern blots of the positive PAC clones and of human genomic DNA, digested with Hind III, which will be hybridized with Exon-specific DNA probes (Vitek et al., 1984; Xu et al., 1994). The PAC clone(s) containing all of the human Exons, with the correct DNA sequences and restriction maps matching human genomic DNA, are then used for generating the "human-NOS2" transgenic
- 15 mouse.

EXAMPLE 2***Making the "human-NOS2" Transgenic Mouse***

- The entire human-NOS2 gene is used to generate the "human-NOS2"
- 20 transgenic mouse by conventional methods with a service provider such as DNX (Princeton, New Jersey, USA). Briefly, DNA from a PAC clone that meets all of the criteria listed above for containing a human NOS2 gene, is used to generate transgenic mice. PAC clone #2 contains both the Promoter/Exon-1 region and the Exon-27 region of the human--NOS2 gene in about 100 kbp of human genomic DNA. PAC
- 25 clone DNA is purified according to the instructions provided by the provider. PAC clone #2 is linearized with Not I. Not I is reported not to cleave the human NOS2 gene and it does not cleave the human NOS2 gene in PAC clone #2 which has been isolated, but Not I does cleave at both ends of the PAC vector as confirmed by pulse-field agarose gel electrophoresis. Linearized DNA is then injected into the pronucleus
- 30 of a fertilized mouse egg by the service provider. The injected eggs are reimplanted into pseudopregnant female mice who then give birth to the babies, the putative F₀ founders.

Genomic DNA extracted from snips of the end of the tails (snips of typically 2 to 5 mm in length) of the fully weaned pups are used to obtain the genotypes of each animal including putative "human-NOS2" transgenic mice (Xu et al. 1996a). After about 3 weeks when the pups are weaned, tail snips are taken and identification tags placed on each animal's ears. Genomic DNA is then extracted from the tails of these F₀ mice (putative founders). Tail snips are minced with a fresh razor blade, placed in 0.4 ml of TE (10mM Tris-HCl, pH 7.4 and 1 mM EDTA, pH 7.4), extracted twice with 2 volumes of phenol:chloroform:isoamyl alcohol (50:48:2), re-extracted with 2 volumes of chloroform:isoamyl alcohol (24:1) and re-extracted with 2 volumes of ether. Residual ether in the aqueous phase is removed by drying under a stream of nitrogen gas. This DNA is genotyped by PCR for the presence of the human NOS2 gene using human-specific DNA probes from human NOS2's Promoter/Exon-1 region (Forward Promoter Primer = CCTTTCCTTCCAAAAACCTC; Reverse Exon-1 Primer = TCACCCAACCCACCTCTTTC to give a 345 bp product). A second PCR from the mouse TAU gene is also performed as a control for the PCR technique and for the presence of mouse DNA using a forward primer (TAU Exon-14 Forward Primer = TTGGCACTTCGATGATGACCTC) and reverse primer (TAU Exon-14 Reverse Primer = CATTGTGACGTGTGATGAGGGG) which give a PCR product of 420 bp whose sequence matches that reported (Andreadis et al., 1992). Southern blots of genomic DNA digested with Hind III and hybridized with the pIN-2 probe (spanning positions +2401 to +4203 of the human NOS2 cDNA which corresponds to Exon-18 to Exon-27 of the human NOS2 gene), are also employed. In this Southern paradigm, human NOS2 gene gives multiple bands of 12, 9.5, 8, 6, 4.5, 4 and 3.6 kBp, while mouse genomic DNA gives only one band of 7.6 kBp (Xu et al. 1994). Hybrid mice containing the human NOS2 and the mouse NOS2 genes contain the mouse-specific 7.6 kBp band and all 7 of the human-specific bands. In an alternative Southern paradigm, BamHI digest of genomic DNA probed with oligonucleotides from the sequence for Exon-18 are predicted to give a 14 kBp band from wild-type mouse DNA, a 10 kBp band from mu-NOS2-knockout DNA and a 2 kBp band from human DNA (Laubach et al., 1995; Xu et al. 1996b). Non-transgenics have a 14 kBp band hybridizing to an Exon-18 probe, while the hemizygous "human NOS2" transgenic mouse display bands at 14 kBp and at 2 kBp hybridizing to the Exon-18 probe.

F₀ mice containing the human NOS2 gene are mated to wild-type mice and their offspring (F₁ generation), ear tagged and genotyped for the presence of the human-NOS2 gene from tail snip DNAs as described above. F₁ mice carrying the human NOS2 gene have passed this gene through the germ line and are hemizygous.

- 5 These mice are then be used for matings as described below.

EXAMPLE 3

Breeding and Identifying a "Humanized-NOS2" Transgenic Mouse

- Mice hemizygous for the human NOS2 gene (generated as described above)
- 10 are mated to NOS2 knockout mice to generate a transgenic mouse expressing only human NOS2 gene products. The simplest way to generate such a mouse is to mate the hemizygous human NOS2 mice (which are +/0 with respect to the human NOS2 gene and +/+ with respect to the murine NOS2 gene) with homozygous NOS2 knockout mice (which are -/- with respect to the murine NOS2 gene and lack
- 15 functional muNOS2 genes). The resulting F1 hybrids of this first cross display an "H-Mm" genotype (arbitrary letter designation) which is +/0 for the huNOS2 gene and +/- for the muNOS2 gene and a "Mm" genotype which is -/- for huNOS2 and +/- for muNOS2. Equal numbers of the "H-Mm" and "Mm" genotypes are observed in this cross. Mice of the "H-Mm" genotype are then mated again to the muNOS2 knockout
- 20 mice (homozygous -/- for functional muNOS2) to generate F2 hybrid mice that display a "H-mm" genotype which is +/0 for huNOS2 gene and -/- for muNOS2 gene and a "Mm" genotype which is -/- for huNOS2 and +/- for muNOS2. Equal numbers of the "H-mm" and the "Mm" genotypes are observed in this cross. The "H-mm" genotype mice are then characterized for the expression of only human NOS2 gene
- 25 products and the nitric oxide produced from the human NOS2 gene products is found to be expressed in a human specific pattern.

Several methods are available to confirm the genotype of the transgenic mice.

- A PCR strategy with a promoter/Exon-1 primer pair gives a specific band from the human NOS2 transgene DNA of about 477 bp. Also, as an alternative Southern
- 30 paradigm, BamH1 digests of genomic DNA probed with oligonucleotides from the sequence of Exon-18 are predicted to give a 14 kBp band from wild-type mouse DNA, a 10 kBp band from muNOS2 knockout DNA and a 2 kBp band from human DNA (Laubach et al, 1995; Xu et al 1996b). "H-Mm" mice display Exon-18

hybridizing bands at 2 kbp (from huNOS2), 14 kbp (from muNOS2) and 10 kbp (from the disrupted muNOS2 gene of knockout mice). "Mm" mice display Exon-18 hybridizing bands at 14 kbp and at 10 kbp. "H-mm" mice display Exon-18 hybridizing bands at 2 kbp and at 10 kbp. In this way, one can use Southern blots of tail snip DNA to diagnose the genotype of each of the transgenic hybrid mouse strains. As another alternative, one can perform test matings by crossing "H-mm" mice to "mm" muNOS2 knockout mice which will give half of the offspring carrying the human NOS2 transgene and the other half lacking it.

10

EXAMPLE 4

Characterizing Human-NOS2 Gene Products

Human NOS2 transgene expression is assessed at the RNA and at the protein levels. To measure human NOS2-mRNA, RNA is extracted from brain, denatured and Northern-blot the RNA, hybridize to the human-specific NOS2 probe and examined for bands of about 4.2 kbp in size as reported by Charles et al. (1993). Although mouse NOS2 mRNA has been reported to also run in the 4 kbp range (Laubach et al. 1995), it should not cross-hybridize to our probe which derives from human NOS2 Exons-1, -2 and -3 which are specific for the human-NOS2 sequence and do not share homology with the mouse NOS2 gene or with any non-human-NOS2 sequence reported in Genbank. As a positive control for hybridization, probe with an APP cDNA for bands in the 3 kbp range (Vitek et al. 1988). If the human-NOS2 transgene is being transcribed and post-transcriptionally spliced in mice, in a manner similar to that found in humans, then animals carrying the human-NOS2 transgene express RNA transcripts that hybridize to the human-specific NOS2 probe while wild-type mice, lacking the transgene, will not display hybridizing transcripts as visualized on Northern blots.

The human iNOS protein and the mouse iNOS protein share high homology at the amino acid sequence level. Although several commercially available antibodies recognize 130 kDa bands on Western blots, the inability of these antibodies to discriminate human from mouse proteins leads us to propose this method only if Northern blots fail to provide the desired information. Thus, a combination of DNA-genotype and bands on a Western could be used to diagnose the presence of human iNOS protein product of the human NOS2 transgene.

EXAMPLE 5***Uses of Humanized-NOS2 Mice***

A "Humanized-NOS2" transgenic mouse expressing only human iNOS protein, is initially useful to test whether the regulation of human-NOS2 induction follows a human-specific or a mouse-specific pattern when in a mouse host. The induction pattern is measured following stimulation of nitric oxide synthase activity with various inducers by indirectly measuring nitrite as a marker of enzymatically-generated nitric oxide release. Since the levels of enzymatic activity of eNOS and nNOS are typically constitutive in peritoneal macrophages and represent a fraction of the inducible iNOS activity which they possess, then peritoneal macrophages are harvested from wild-type, muNOS2 knockout and from "Humanized-NOS2" transgenic mice for placement in culture and treatment with stimulating agents followed by nitrite (nitric oxide) measurement. Laubach et al. (1995) report that elicited peritoneal macrophages from wild-type mice, treated with lipopolysaccharide (LPS) and Interferon-gamma (IFN-gamma), have about 15 times more NOS activity than similarly treated cells of NOS2 knockout mice. MacMicking et al. report that nitrite levels in elicited peritoneal macrophages from wild-type mice treated with LPS and/or IFN-gamma, are at least 15 fold higher than similarly treated cells of a different NOS2 knockout mouse (MacMicking et al., 1995). Weinberg et al. (1995) report that human peritoneal macrophages produce little or no nitrite (ie. nitric oxide) before or after treatment with LPS, IFN-gamma or both. These data indicate that a mouse-specific pattern of nitric oxide production in elicited peritoneal macrophages would include stimulation by LPS or IFN-gamma and that a human-specific pattern would be a lack of nitric oxide production following stimulation with these agents. As suggested by Ding et al (1997), iNOS activity and nitrite release are increased following stimulation of human microglia, the brain-specific macrophage, with a combination of Interferon-gamma and Interleukin-1 beta (IL-1beta). This combination of IFN-gamma and IL-1beta are used as a positive control to show that the peritoneal macrophages from various mice are capable of showing an inducible rise in nitrite levels. Alternatively, one can culture microglia from the various mice and test their responses to these inducers.

Specific methods for obtaining peritoneal macrophages, measuring nitrite via Greiss reaction and culturing mouse brain microglia are found in Laubach et al. and

Colton et al. (Colton and Gilbert, 1993; Laubach et al., 1995). Briefly, macrophages are elicited by intraperitoneal (i.p.) injection of 2 ml of 4% Brewer thioglycollate (Difco). Four days following injection, cells are harvested by washing out the peritoneal cavity with 20 ml of cold phosphate buffered saline and the entire solution centrifuged to pellet the cells. Cells are resuspended in 20 ml of RPMI 1640 with 10% fetal bovine serum (RPMI-FBS) (Gibco-BRL-Life Technologies), centrifuged, cell pellets resuspended in RPMI-FBS and plated in 4 x 35 mm tissue culture dishes per mouse. After 3 hours at 37°C to allow cells to attach, non-adherent cells are removed with 3 washes of RPMI-FBS and adherent cells used for stimulation experiments. Adherent cells are treated with nothing (as a non-stimulated control), murine IFN-gamma (100 units/ml, Boehringer Mannheim) or LPS (1 µg/ml, E. coli 055:B5, Sigma) for 12, 24, 36, and 48 hours. At each time point, quadruplicate 50 µl aliquots of conditioned media are removed to 96 well tissue culture plates and nitrite levels assayed with the Greiss reaction. Briefly, an equal 50 µl aliquot of Greiss reagent (a 1:1 solution of 0.1% N-(1-naphthyl)ethylenediamine dihydrochloride: 1% sulfanilamide in 5% phosphoric acid), incubated for 10 minutes at room temperature, and absorbance read at 544 nm of a plate reader. Sodium nitrite standards were employed to generate a standard curve of the colorimetric response. The method of Colton et al. is employed to prepare primary cultures of mouse brain microglia and test their responses to stimuli with the Greiss reaction listed above (Colton and Gilbert, 1993).

The foregoing is illustrative of the present invention, and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.

25

References

- Andreadis, A., et al., (1992). *Biochem.* 31, 10626-10633.
- Beckman, J. S. (1996). *Chem. Res. Tox.* 9: 836-44.
- Charles, I. G., et al., (1993). *Proc. Natl. Acad. Sci. U.S.A.* 90, 11419-23.
- Colton, C., et al., (1996). *Mol Chem Neuropathol* 28, 15-20.
- Colton, C. A., and Gilbert, D. L. (1993). *Adv Neurol* 59, 321-6.
- Ding, M., et al., (1997). *J. Biol. Chem.* 272, 11327-35.
- Eikelenboom, P., et al., (1996). *Neurobiol. Aging*, 673-80.

30

- Han, S. H., et al., (1994). *J Neuropathol Exp Neurol* 53, 535-44.
- Laubach, V. E., et al., (1995). *Proc. Natl. Acad. Sci. U.S.A.* 92, 10688-92.
- MacMicking, J. D., et al., (1995). *Cell* 81, 641-50.
- Mecocci, P., et al., (1993). *Ann Neurol* 34, 609-16.
- 5 Meda, L., et al., (1995). *Nature* 374, 647-50.
- Mitsuda, N., et al., (1997). *J. Biol. Chem.* in press.
- Perlmutter, L., et al., (1990). *Neurosci. Ltrs.* 119, 32-36.
- Rogers, J., et al., (1993). *Neurology* 43: 1609-11.
- Sano, M., et al., (1997). *New England Journal of Medicine* 336, 1216-22.
- 10 Smith, M. A., et al., (1997). *J. Neurosci.* 17, 2653-7.
- Smith, M. A., et al., (1996). *Mol Chem Neuropathol* 28, 41-8.
- Snell, J., and Colton, C. (1997). Submitted.
- Spitsin, S. V., et al., (1996). *Mol Med* 2, 226-35.
- Sullivan, P. M., et al., (1997). *J. Biol. Chem.* in press.
- 15 Vitek, M. P., et al., (1994). *Proc Natl Acad Sci U S A* 91, 4766-70.
- Vitek, M. P., et al., (1984). *Gene Analysis Techniques* 2, 16-21.
- Vitek, M. P., et al., (1988). *Mol. Brain Res* 4, 121-131.
- Vouldoukis, I., et al., (1995). *Proc. Natl. Acad. Sci. U.S.A.* 92, 7804-7808.
- Walker, D. G., et al., (1995). *J. Neurosci. Res.* 40, 478-93.
- 20 Weinberg, J. B., et al., (1995). *Blood* 86, 1184-95.
- Wink, D. (1997). In preparation.
- Xu, P.-T., et al., (1996a). *Neurobiol. Dis.* 3, 229-245.
- Xu, W., et al., (1996b). *Biophys. Res. Comm.* 219, 784-8.
- Xu, W., et al., P. (1994). *Genomics* 21, 419-422.

That which is claimed is:

1. A transgenic mouse whose germ cells and somatic cells contain (i) an inactive mouse inducible nitric oxide synthase gene, and (ii) a transgene encoding the human inducible nitric oxide synthase gene, said transgene including all regulatory elements of the human nitric oxide synthase gene necessary for a human pattern of expression of said transgene in said transgenic mouse.
2. A transgenic mouse according to claim 1, wherein said mouse contains one allele encoding the human inducible nitric oxide synthase gene.
3. A method of determining if a compound is capable of inducing Alzheimer's disease, comprising administering said compound to a mouse of claim 1, and then examining said mouse for one the development of said disease.
4. A method of determining if a compound is capable of inducing Multiple Sclerosis, comprising administering said compound to a mouse of claim 1, and then examining said mouse for the development of said disease.
5. A method of determining if a compound is capable of inducing Inflammatory Bowel Disease, comprising administering said compound to a mouse of claim 1, and then examining said mouse for the development of said disease.
6. A method of determining if a compound is capable of inducing Rheumatoid arthritis, comprising administering said compound to a mouse of claim 1, and then examining said mouse for the development of said disease.

7. A method of screening a compound for activity in treating Alzheimer's disease, comprising administering said compound to a mouse of claim 1, and then examining said mouse for the treatment of said disease.

5 8. A method of screening a compound for activity in treating Multiple Sclerosis, comprising administering said compound to a mouse of claim 1, and then examining said mouse for the treatment of said disease.

10 9. A method of screening a compound for activity in treating Inflammatory Bowel Disease, comprising administering said compound to a mouse of claim 1, and then examining said mouse for the treatment of said disease.

15 10. A method of screening a compound for activity in treating Rheumatoid arthritis, comprising administering said compound to a mouse of claim 1, and then examining said mouse for the treatment of said disease.

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

Attorney Docket No. 5405-214

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **TRANSGENIC MODEL OF HUMAN OXIDATIVE STRESS**

the specification of which

☐ is attached hereto

OR

☒ was filed on January 19, 2001 as United States Application Serial No. 09/744,133 or PCT International Application Number _____ and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate, or of any PCT International application having a filing date before that of the application on which priority is claimed.

None			<input type="checkbox"/> Yes <input type="checkbox"/> No
Number	Country	MM/DD/YYYY Filed	Priority Claimed
			<input type="checkbox"/> Yes <input type="checkbox"/> No
Number	Country	MM/DD/YYYY Filed	Priority Claimed
			<input type="checkbox"/> Yes <input type="checkbox"/> No
Number	Country	MM/DD/YYYY Filed	Priority Claimed

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

None	
Application Number(s)	Filing Date (MM/DD/YYYY)
Application Number(s)	Filing Date (MM/DD/YYYY)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application (37 C.F.R. § 1.63(d)).

PCT/US99/16338	19 July 1999	Pending
Appln. Serial No.	Filing Date	Status Patented/Pending/Abandoned
Appln. Serial No.	Filing Date	Status Patented/Pending/Abandoned
Appln. Serial No.	Filing Date	Status Patented/Pending/Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

USPTO Customer Number 20792

Send correspondence to: Kenneth D. Sibley
Myers Bigel Sibley & Sajovec
Post Office Box 37428
Raleigh, North Carolina 27627

Direct telephone calls to: Kenneth D. Sibley
(919)854-1400

Facsimile: (919) 854-1401

Full name of sole inventor: Michael P. Vitek

Inventor's

Signature: [Handwritten Signature] Date: 13 Mar 01

Residence: Apex, North Carolina NC

Citizenship: United States of America

Post Office Address: 205 Park Knoll Lane
Apex, North Carolina 27502